borderline non-significantp = .075
Secondary outcome: aspartate aminotransferase According to our meta-analysis with WMD as the summary estimate, a borderline non-significant reduction of AST levels in statin recipients (WMD (95% CI) = −8.45 (−17.34, 0.44), p = .075) was noted ( Figure 4 ).